The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Plasminogen activation and cancer
Abstract
Summary: Breakdown of the extracellular matrix is crucial for cancer invasion and metastasis. It is accomplished by the concerted action of several proteases, including the serine protease plasmin and a number of matrix metalloproteases. The activity of each of these proteases is regulated by an array of activators, inhibitors and cellular receptors. Thus, the generation of plasmin involves the pro-enzyme plasminogen, the urokinase type plasminogen activator uPA and its pro-enzyme pro-uPA, the uPA inhibitor PAI-1, the cell surface uPA receptor uPAR, and the plasmin inhibitor α2-antiplasmin. Furthermore, the regulation of extracellular proteolysis in cancer involves a complex interplay between cancer cells and non-malignant stromal cells in the expression of the molecular components involved. For some types of cancer, this cellular interplay mimics that observed in the tissue of origin during non-neoplastic tissue remodelling processes. We propose that cancer invasion can be considered as uncontrolled tissue remodelling. Inhibition of extracellular proteases is an attractive approach to cancer therapy. Because proteases have many different functions in the normal organism, efficient inhibition will have toxic side effects. In cancer invasion, like in normal tissue remodelling processes, there appears to be a functional overlap between different extracellular proteases. This redundancy means that combinations of protease inhibitors must be used. Such combination therapy, however, is also likely to increase toxicity. Therefore for each type of cancer, a combination of protease inhibitors that is optimised with respect to both maximal therapeutic effect and minimal toxic side effects need to be identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Plasminogen Activators, Tissue Degradation, and Cancer
(1985) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60028-7 · Cited by 2,535
Heissig, B., Hattori, K., Dias, S., Friedrich, M., Ferris, B., Hackett, N. R., Crystal, R. G., Besmer, P., Lyden, D., Moore, M. A. S., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00754-7 · Cited by 1,751
Guy, C. T., Cardiff, R. D., & Muller, W. J. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.3.954 · Cited by 1,631
The urokinase-type plasminogen activator system in cancer metastasis: A review
Andreasen, P. A., Kjøller, L., Christensen, L., & Duffy, M. J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z · Cited by 1,546
MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis
Coussens, L. M., Tinkle, C. L., Hanahan, D., & Werb, Z. (2000) · Cell · doi:10.1016/s0092-8674(00)00139-2 · Cited by 1,306
Physiological consequences of loss of plasminogen activator gene function in mice
Carmeliet, P., Schoonjans, L., Kieckens, L., Ream, B., Degen, J., Bronson, R., De Vos, R., van den Oord, J. J., Collen, D., & Mulligan, R. C. (1994) · Nature · doi:10.1038/368419a0 · Cited by 1,037
A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.
Vassalli, J. D., Baccino, D., & Belin, D. (1985) · The Journal of cell biology · doi:10.1083/jcb.100.1.86 · Cited by 712
Antibodies to plasminogen activator inhibit human tumor metastasis
Ossowski, L., & Reich, E. (1983) · Cell · doi:10.1016/0092-8674(83)90093-4 · Cited by 634
Roldan, A. L., Cubellis, M. V., Masucci, M. T., Behrendt, N., Lund, L. R., Danø, K., Appella, E., & Blasi, F. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08132.x · Cited by 603
Self-citationImpaired wound healing in mice with a disrupted plasminogen gene
Rømer, J., Bugge, T. H., Fyke, C., Lund, L. R., Flick, M. J., Degen, J. L., & Danø, K. (1996) · Nature Medicine · doi:10.1038/nm0396-287 · Cited by 561
Self-citationLund, L. R., Rømer, J., Thomasset, N., Solberg, H., Pyke, C., Bissell, M. J., Danø, K., & Werb, Z. (1996) · Development · doi:10.1242/dev.122.1.181 · Cited by 546
Self-citationGoss, K. H., Matrisian, L. M., Jensen, R. A., & Rodgers, W. H. (1996) · Europe PMC (PubMed Central) · Cited by 504
Ellis, V., Behrendt, N., & Danø, K. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98963-5 · Cited by 498
Self-citationPyke, C., Kristensen, P. K., Ralfkiaer, E. M., Grøndahl-Hansen, J., Eriksen, J., Blasi, F., & Danø, K. (1991) · PubMed · Cited by 471
Self-citationPlasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.
Bugge, T. H., Flick, M. J., Daugherty, C. C., & Degen, J. L. (1995) · Genes & Development · doi:10.1101/gad.9.7.794 · Cited by 438
Fibrinolysis Associated with Oncogenic Transformation
Unkeless, J. C., Danø, K., Kellerman, G. M., & Reich, E. (1974) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)42516-7 · Cited by 437
Self-citationLoss of Fibrinogen Rescues Mice from the Pleiotropic Effects of Plasminogen Deficiency
Bugge, T. H., Kombrinck, K. W., Flick, M. J., Daugherty, C. C., Danton, M. J. S., & Degen, J. L. (1996) · Cell · doi:10.1016/s0092-8674(00)81390-2 · Cited by 424
Grøndahl-Hansen, J., Christensen, I. J., Rosenquist, C., Brünner, N., Mouridsen, H. T., Danø, K., & Blichert-Toft, M. (1993) · PubMed · Cited by 380
Self-citationCancer invasion and tissue remodeling: common themes in proteolytic matrix degradation
Johnsen, M., Lund, L. R., Rømer, J., Almholt, K., & Danø, K. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80044-6 · Cited by 356
Self-citationMadlener, M., Parks, W. C., & Werner, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4049 · Cited by 335
Pyke, C., Ralfkiaer, E. M., Huhtala, P., et al. (1992) · PubMed · Cited by 328
Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice
Arbeit, J. M., Münger, K., Howley, P. M., & Hanahan, D. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4358-4368.1994 · Cited by 305
Cancer invasion and tissue remodeling‐cooperation of protease systems and cell types
DANØ, K., RØMER, J., NIELSEN, B. S., BJØRN, S., PYKE, C., RYGAARD, J., & LUND, L. R. (1999) · APMIS · doi:10.1111/j.1699-0463.1999.tb01534.x · Cited by 291
Self-citationPlasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis
Stephens, R. W. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.10.869 · Cited by 279
Bugge, T. H., Flick, M. J., Danton, M. J., Daugherty, C. C., Romer, J., Dano, K., Carmeliet, P., Collen, D., & Degen, J. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5899 · Cited by 276
Functional overlap between two classes of matrix-degrading proteases in wound healing
Lund, L. R. (1999) · The EMBO Journal · doi:10.1093/emboj/18.17.4645 · Cited by 270
Self-citationUrokinase Receptor (CD87) Regulates Leukocyte Recruitment via β2 Integrins In Vivo
May, A. E., Kanse, S. M., Lund, L. R., Gisler, R. H., Imhof, B. A., & Preissner, K. T. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.6.1029 · Cited by 270
Self-citationUrokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.
Min, H. Y., Doyle, L. V., Vitt, C. R., Zandonella, C., Stratton-Thomas, J. R., Shuman, M. A., & Rosenberg, S. (1996) · PubMed · Cited by 242
Grøndahl-Hansen, J., Lund, L. R., Ralfkiær, E., Ottevanger, V., & Danø, K. (1988) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12461511 · Cited by 239
Self-citationPetersen, L. C., Lund, L. R., Nielsen, L. S., Danø, K., & Skriver, L. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)37940-7 · Cited by 231
Self-citationBugge, T. H., Suh, T. T., Flick, M. J., Daugherty, C. C., R, J., Solberg, H., Ellis, V., Danø, K., & Degen, J. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16886 · Cited by 218
Self-citationGutierrez, L. S., Schulman, A., Brito-Robinson, T., Noria, F., Ploplis, V. A., & Castellino, F. (2000) · PubMed · Cited by 217
Gyetko, M. R., Sud, S., Kendall, T., Fuller, J. A., Newstead, M. W., & Standiford, T. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.3.1513 · Cited by 201
Tissue plasminogen activator in central nervous system physiology and pathology
Melchor, J. P., & Strickland, S. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-12-0838 · Cited by 193
Harbeck, N., Kates, R. E., Look, M. P., Gelder, M. E. M., Klijn, J. G. M., Krüger, A., Kiechle, M. B., Jänicke, F., Schmitt, M., & Foekens, J. A. (2002) · PubMed · Cited by 191
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.
Pyke, C., Græm, N., Ralfkiaer, E. M., Rønne, E., Høyer‐Hansen, G., Brünner, N., & Danø, K. (1993) · PubMed · Cited by 186
Self-citationPloug, M., Østergaard, S., Gårdsvoll, H., Kovalski, K., Holst-Hansen, C., Holm, A., Ossowski, L., & Danø, K. (2001) · Biochemistry · doi:10.1021/bi010662g · Cited by 176
Self-citationHuman Collagenase-3 Is Expressed in Malignant Squamous Epithelium of the Skin
Airola, K., Johansson, N., Kariniemi, A.-L., Kähäri, V.-M., & Saarialho-Kere, U. K. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12319441 · Cited by 175
Urokinase Receptor Is Necessary for Adequate Host Defense Against Pneumococcal Pneumonia
Rijneveld, A. W., Levi, M., Florquin, S., Speelman, P., Carmeliet, P., & van der Poll, T. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3507 · Cited by 175
Matrix Metalloproteinases and Tumor Progression
Freije, J. M. P., Balbín, M., Pendás, A. M., Sánchez, L. M., Puente, X. S., & López-Otín, C. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0081-0_9 · Cited by 174
The breast cancer-associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis.
Lefebvre, O., Wolf, C., Limacher, J. M., Hutin, P., Wendling, C., LeMeur, M., Basset, P., & Rio, M. C. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.4.997 · Cited by 173
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Grøndahl-Hansen, J., Peters, H. A., van Putten, W. L., Look, M. P., Pappot, H., Rønne, E., Danø, K., Klijn, J. G. M., Brünner, N., & Foekens, J. A. (1995) · PubMed · Cited by 173
Self-citationImmunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.
Skriver, L., Larsson, L. I., Kielberg, V, Nielsen, L. S., Andresen, P. B., Kristensen, P., & Danø, K. (1984) · The Journal of cell biology · doi:10.1083/jcb.99.2.753 · Cited by 169
Self-citationPloug, M. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454630 · Cited by 160
Self-citationA plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation
Selvarajan, S., Lund, L. R., Takeuchi, T., Craik, C. S., & Werb, Z. (2001) · Nature Cell Biology · doi:10.1038/35060059 · Cited by 157
Self-citationRegulation of cell adhesion by PAI‐1
Loskutoff, D. J., Curriden, S. A., Hu, G., & Deng, G. (1999) · Apmis · doi:10.1111/j.1699-0463.1999.tb01526.x · Cited by 155
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice
Almholt, K., Lund, L. R., Rygaard, J., Nielsen, B. S., Danø, K., Rømer, J., & Johnsen, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20631 · Cited by 155
Self-citationRømer, J., Lund, L. R., Eriksen, J., Ralfkiaer, E. M., Zeheb, R., GELEHRTER, T. D., Danø, K., & Kristensen, P. K. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12486833 · Cited by 154
Self-citationBugge, T. H., Lund, L. R., Kombrinck, K. K., Nielsen, B. S., Holmbäck, K., Drew, A. F., Flick, M. J., Witte, D. P., Danø, K., & Degen, J. L. (1998) · Oncogene · doi:10.1038/sj.onc.1201869 · Cited by 153
Self-citationRømer, J., Lund, L. R., Eriksen, J., Pyke, C., Kristensen, P., & Danø, K. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12373187 · Cited by 143
Self-citationMutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice
Oh, J., Takahashi, R., Adachi, E., Kondo, S., Kuratomi, S., Noma, A., Alexander, D. B., Motoda, H., Okada, A., Seiki, M., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207688 · Cited by 142
Lijnen, R. H., & Collen, D. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-11-0724 · Cited by 140
Potent antitumor activity of a urokinase-activated engineered anthrax toxin
Liu, S., Aaronson, H., Mitola, D. J., Leppla, S. H., & Bugge, T. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0236849100 · Cited by 124
Kjøller, L. (2002) · Biological Chemistry · doi:10.1515/bc.2002.002 · Cited by 122
Lactational competence and involution of the mouse mammary gland require plasminogen
Lund, L. R., Bjørn, S. F., Sternlicht, M. D., Nielsen, B. S., Solberg, H., Usher, P. A., Østerby, R., Christensen, I. J., Stephens, R. W., Bugge, T. H., et al. (2000) · Development · doi:10.1242/dev.127.20.4481 · Cited by 116
Self-citationNielsen, B. S., Sehested, M., Timshel, S., Pyke, C., & Danø, K. (1996) · PubMed · Cited by 114
Self-citationBehrendt, N. (2004) · Biological Chemistry · doi:10.1515/bc.2004.031 · Cited by 101
Self-citationKristensen, P. K., Eriksen, J., & Danø, K. (1991) · Journal of Histochemistry & Cytochemistry · doi:10.1177/39.3.1899685 · Cited by 94
Self-citationUrokinase‐type plasminogen activator and its receptor synergize to promote pathogenic proteolysis
Zhou, H., Nichols, A., Meda, P., & Vassalli, J. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4817 · Cited by 94
Stromal Cell Expression of Components of Matrix-Degrading Protease Systems in Human Cancer
Hewitt, R. E., & Danø, K. (2017) · Enzyme and Protein · doi:10.1159/000468623 · Cited by 82
Self-citationStromal Cell Involvement in Cancer
Almholt, K., & Johnsen, M. (2003) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-59349-9_3 · Cited by 79
Self-citationUsher, P. A., Thomsen, O., Iversen, P., Johnsen, M., Brünner, N., Høyer‐Hansen, G., Andreasen, P. A., Danø, K., & Nielsen, B. S. (2004) · International Journal of Cancer · doi:10.1002/ijc.20665 · Cited by 74
Self-citationUrokinase Plasminogen Activator Is Localized in Stromal Cells in Ductal Breast Cancer
Nielsen, B. S., Sehested, M., Duun, S., Rank, F. E., Timshel, S., Rygaard, J., Johnsen, M., & Danø, K. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780363 · Cited by 73
Self-citationA functional overlap of plasminogen and MMPs regulates vascularization during placental development
Solberg, H., Rinkenberger, J. L., Danø, K., Werb, Z., & Lund, L. R. (2003) · Development · doi:10.1242/dev.00642 · Cited by 72
Self-citationFrandsen, T. L., Holst‐Hansen, C., Nielsen, B. S., Christensen, I. J., Nyengaard, J. R., Carmeliet, P., & Brünner, N. (2001) · PubMed · Cited by 63
Anthrax toxin: structures, functions and tumour targeting
Liu, S., Schubert, R. L., Bugge, T. H., & Leppla, S. H. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.5.843 · Cited by 59
The urokinase receptor and the regulation of cell proliferation
Mazzieri, R., & Blasi, F. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-01-0021 · Cited by 53
Cadd, T. L., & Patterson, J. L. (1994) · Journal of Virology · doi:10.1128/jvi.68.1.358-365.1994 · Cited by 37
Rømer, J., Pyke, C., Lund, L. R., Danø, K., & Ralfkiaer, E. M. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2001.01241.x · Cited by 36
Self-citationAlmasi, C. E., Høyer‐Hansen, G., Christensen, I. J., Danø, K., & Pappot, H. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.11.020 · Cited by 32
Self-citationPlasminogen Mediates the Pathological Effects of Urokinase-Type Plasminogen Activator Overexpression
Bolon, I., Zhou, H., Charron, Y., Wohlwend, A., & Vassalli, J. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63786-8 · Cited by 25
Cited by
Turning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
Regulation of cell signalling by uPAR
Smith, H. W., & Marshall, C. J. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2821 · Cited by 960
Fibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 926
Molecular mechanisms of cancer development in obesity
Khandekar, M. J., Cohen, P., & Spiegelman, B. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3174 · Cited by 907
Metastasis: recent discoveries and novel treatment strategies
Eccles, S. A., & Welch, D. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60781-8 · Cited by 721
Metadata
- Authors
- Behrendt, N., Høyer-Hansen, G., Johnsen, M., Lund, L. R., Ploug, M., Rømer, J., & Danø, K.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2005
- Volume
- 93
- Issue
- 04
- Pages
- 676-681
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2065791048
- Cited by
- 452
- References
- 73
- FWCI
- 11.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.